Adage Capital Partners
SYRE icon

Adage Capital Partners’s Spyre Therapeutics SYRE Stock Holding History

Adage Capital Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153M Buy
+1,722,300
New +$126M 0.21% 79
2025
Q3 		– Sell
-610,200
Closed -$9.13M – 972
2025
Q2 		$9.13M Sell
610,200
-193,000
-24% -$2.86M 0.02% 632
2025
Q1 		$13M Sell
803,200
-226,800
-22% -$4.72M 0.02% 529
2024
Q4 		$24M Sell
1,030,000
-25,000
-2% -$733K 0.04% 396
2024
Q3 		$31M Sell
1,055,000
-97,411
-8% -$2.71M 0.05% 331
2024
Q2 		$27.1M Buy
1,152,411
+47,211
+4% +$1.59M 0.05% 361
2024
Q1 		$41.9M Buy
1,105,200
+105,200
+11% +$3.05M 0.08% 267
2023
Q4 		$21.5M Buy
+1,000,000
New +$13.8M 0.04% 408
2023
Q2 		– Sell
-60,000
Closed -$435K – 926
2023
Q1 		$435K Hold
60,000
– – ﹤0.01% 820
2022
Q4 		$675K Hold
60,000
– – ﹤0.01% 855
2022
Q3 		$789K Hold
60,000
– – ﹤0.01% 898
2022
Q2 		$758K Buy
+60,000
New +$2.1M ﹤0.01% 933
2022
Q1 		– Sell
-40,000
Closed -$4.75M – 1132
2021
Q4 		$4.75M Sell
40,000
-100,000
-71% -$15.8M 0.01% 821
2021
Q3 		$27.8M Buy
140,000
+18,017
+15% +$3.15M 0.05% 352
2021
Q2 		$21.2M Buy
121,983
+4,057
+3% +$737K 0.04% 446
2021
Q1 		$23.3M Sell
117,926
-1,754
-1% -$337K 0.05% 393
2020
Q4 		$23.5M Hold
119,680
– – 0.05% 379
2020
Q3 		$21.2M Buy
119,680
+4,000
+3% +$740K 0.05% 358
2020
Q2 		$26.8M Buy
115,680
+56,936
+97% +$10.8M 0.07% 312
2020
Q1 		$6.84M Hold
58,744
– – 0.02% 532
2019
Q4 		$11.2M Hold
58,744
– – 0.03% 519
2019
Q3 		$11.3M Hold
58,744
– – 0.03% 500
2019
Q2 		$10.1M Hold
58,744
– – 0.03% 531
2019
Q1 		$11.8M Buy
58,744
+400
+0.7% +$83.4K 0.03% 496
2018
Q4 		$10.9M Buy
58,344
+21,716
+59% +$4.61M 0.03% 491
2018
Q3 		$8.76M Buy
36,628
+1,000
+3% +$234K 0.02% 564
2018
Q2 		$9.42M Buy
35,628
+25,628
+256% +$6.31M 0.02% 573
2018
Q1 		$2.48M Buy
+10,000
New +$1.81M 0.01% 669

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Adage Capital Partners's SYRE Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 1,722,300 shares worth $153M. The stake represents 0.21% of the portfolio and ranks #79 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in SYRE as recently as Q2 2025.

Adage Capital Partners first reported a position in SYRE in Q1 2018 and has held it in 28 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Adage Capital Partners held 1,722,300 shares of Spyre Therapeutics worth $153M as of Q2 2026.
  • Spyre Therapeutics was a new Adage Capital Partners position in Q2 2026.
  • Spyre Therapeutics made up 0.21% of Adage Capital Partners's portfolio in Q2 2026, its #79 holding.
  • Adage Capital Partners first reported a position in Spyre Therapeutics in Q1 2018 and has held it in 28 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.